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Background. Limited data exist on human immunodeﬁciency virus (HIV)-infected individuals’ ability to work after receiving
combination antiretroviral therapy (cART). We aimed to investigate predictors of regaining full ability to work at 1 year after starting
cART.
Methods. Antiretroviral-naive HIV-infected individuals <60 years who started cART from January 1998 through December
2012 within the framework of the Swiss HIV Cohort Study were analyzed. Inability to work was deﬁned as a medical judgment
of the patient’s ability to work as 0%.
Results. Of 5800 subjects, 4382 (75.6%) were fully able to work, 471 (8.1%) able to work part time, and 947 (16.3%) were unable
to work at baseline. Of the 947 patients unable to work, 439 (46.3%) were able to work either full time or part time at 1 year of
treatment. Predictors of recovering full ability to work were non-white ethnicity (odds ratio [OR], 2.06; 95% conﬁdence interval
[CI], 1.20–3.54), higher education (OR, 4.03; 95% CI, 2.47–7.48), and achieving HIV-ribonucleic acid <50 copies/mL (OR, 1.83;
95% CI, 1.20–2.80). Older age (OR, 0.55; 95% CI, .42–.72, per 10 years older) and psychiatric disorders (OR, 0.24; 95% CI,
.13–.47) were associated with lower odds of ability to work. Recovering full ability to work at 1 year increased from 24.0% in
1998–2001 to 41.2% in 2009–2012, but the employment rates did not increase.
Conclusions. Regaining full ability to work depends primarily on achieving viral suppression, absence of psychiatric comorbid-
ity, and favorable psychosocial factors. The discrepancy between patients’ ability to work and employment rates indicates barriers to
reintegration of persons infected with HIV.
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Over the past 20 years, combination antiretroviral therapy
(cART) has improved the prognosis for a close to normal life
expectancy in a considerable proportion of individuals with
human immunodeﬁciency virus (HIV)/acquired immune deﬁ-
ciency syndrome (AIDS) [1]. As a result, individuals previously
unable towork due toHIV-relatedmorbidity are able to return to
work in light of their improved health. Beneﬁts of employment
include economic well being, decreased symptoms of depres-
sion, and improved social support [2–6]. However, barriers to
workforce re-entry have been reported for HIV-infected indi-
viduals, side effects of cART, and discrimination [7–11]. In
2004, a cross-sectional study within the Swiss HIV Cohort
Study (SHCS) estimated an annual productivity loss of 121.9
million Swiss francs (95.2 million US dollars) for approximately
5000 HIV-infected individuals living in Switzerland [4]. Inabil-
ity to work was independently associated with older age, AIDS-
deﬁning disease, history of using of intravenous drugs, and
lower CD4 cell counts, whereas a higher level of education
and a stable partnership were associated with greater ability to
work, suggesting that socioeconomic factors may inﬂuence the
cost-effectiveness of healthcare interventions in individuals in-
fected with HIV. The arrival of new antiretroviral drugs with
improved potency, safety, tolerability, and convenience, and
starting cART earlier in the course of the disease may have af-
fected the level of the ability to work [12, 13]. However, the em-
ployment rates of adults with HIV infection who are living in
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high-income countries are still lower compared with those of
the general population [14, 15].
The overall aim of this study was to investigate the ability to
work in HIV-1-infected adults receiving cART. In particular,
the speciﬁc objectives were to (1) explore predictors of patients
regaining the ability to work full time at 1 year after starting
cART, (2) compare time trends in the ability to work and in
the primary sources of income over a 5-year period in treated
individuals, and (3) investigate the risk factors for developing
a new disability that impaired a patient’s ability to work.
METHODS
Study Design
This study is a subset of the prospective SHCS, with continuous
enrollment of individuals infected with HIV ≥18 years of age
observed in the HIV outpatient clinics of 7 Swiss hospitals
(Basel, Bern, Geneva, Lausanne, Lugano, St. Gallen, Zurich)
and associated smaller hospitals’ and physicians’ practices
[16]. Data were prospectively collected at time of patients’
enrollment in the study and every 6 months thereafter on stan-
dardized data collection forms and include basic sociodemo-
graphic characteristics and information about the clinical
course of the disease, coinfection with hepatitis B and hepatitis
C, psychiatric comorbidity, antiretroviral treatment, comedi-
cation, and immunological and virological parameters. The pa-
tient’s ability to work in the month preceding a follow-up visit
was assessed, independent of the patient’s current employment
status or the patient’s own opinion, by the treating physician
using a scale of 0% to 100% (0% = total disability; 100% = no
disability). In the instruction materials, there were no details
specifying which medicals factors should be calculated in as-
sessing each patient’s ability to work. The patient’s primary
source of income was recorded every 6 months according to
5 main categories ( job, insurance, unemployment beneﬁts, rel-
atives, savings). For the present analysis, we used the SHCS
database extract of June 2014. The local ethical committees of
all participating study sites (Ethics Committee northwest/cen-
tral Switzerland; Ethics Committee Bern, Ethics Committee
Geneva; Ethics Committee St. Gallen, Ethics Committee Ticino;
Ethics Committee Vaud; Ethics Committee Zurich) approved
the study, and written informed consent was obtained from
all participants.
Study Population
Antiretroviral-naive HIV-infected individuals below 60 years
who were participating in the SHCS and started cART between
January 1, 1998 and December 31, 2012, and for whom data on
their ability to work at baseline and after 1 year of treatment
were available, were eligible for this study. Similar to Switzer-
land, the retirement age in our cohort was 65, and we restricted
our analysis to patients younger than 60, accounting for a po-
tential follow-up of 5 years.
Deﬁnitions
“Inability to work” was deﬁned as a medical judgment that the
patient could not pursue any income-producing activities due to
his or her health and was reported as 0% ability. “Partial ability
to work” was deﬁned as a medical judgment of the patient’s
ability to work part time, reported as 1%–99% ability. “Full
work ability” was deﬁned as a medical judgment of the patient’s
ability to work full time, reported as 100% ability. Finally,
“cART” was deﬁned as an antiretroviral regimen containing at
least 3 drugs, ie, 2 nucleos(t)ide reverse-transcriptase inhibitors in
combination with either a nonnucleoside reverse-transcriptase
inhibitor, an integrase inhibitor, or a protease inhibitor. Level
of formal education was noted as 1 of 3 categories: “low” (man-
datory education of up to 9 years), “medium” (mandatory and
vocational education of 9–12 years), or “high” (formal educa-
tion of more than 12 years).
Statistical Analysis
The primary endpoint was the proportion of individuals unable
to work at baseline who recovered sufﬁciently to be able to work
full time at the end of the ﬁrst year of treatment. Secondary end-
points were the proportion of individuals able to work at base-
line who became unable to work at 1 year and at 5 years of
cART, and the changes over time in patients’ ability to work
and in their primary sources of income. Basic sociodemogra-
phic characteristics, comorbidities (including current use of in-
travenous drugs, psychiatric comorbidity), CD4 cell count, HIV
viral load, and ART were compared with respect to the ability to
work at baseline using the χ2 test for categorical variables and
the Mann–Whitney U or the Kruskal-Wallis test for continuous
variables. Logistic regression models were used (1) to investigate
predictors of achieving full ability to work at 1 year in patients
who were unable to work at baseline and (2) to explore risk fac-
tors for a patient’s developing a new disability to work. We in-
troduced mixed-effect models to adjust for the variability of
outcome assessment by physicians. All analyses were performed
using Stata software (version 11 for Windows; StataCorp, Col-
lege Station, TX).
RESULTS
Study Population
Among the more than 18 000 SHCS participants, 6782 antiretro-
viral-naive patients started cART from January 1, 1998 through
December 31, 2012. Of these, we excluded 291 who were more
than 60 years old and 691 for whom no data were available
with respect to their ability to work at baseline or after the ﬁrst
year of treatment. The ﬁnal study population comprised 5800 per-
sons. At baseline, 4382 individuals (75.6%) were fully able to work,
471 (8.1%) were only able to work part time, and 947 (16.3%)
were unable to work at all. Among 471 patients who were classi-
ﬁed as partially able to work, only 12 patients were judged to be
unable to work in a proportion of 10% and 6 patients were as-
sessed to be 90% able to work; all other patients were able to
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work between 20% and 80%. Nobody was assessed to be able to
work below 10% or above 90%. Baseline characteristics according
to the ability to work at starting cART are shown in Table 1.
Ability to Work and the Main Source of Income at 1 Year of Treatment
Of the 947 individuals unable to work at baseline, 508 (53.6%)
were still unable to work at 1 year after starting cART, 310
(32.8%) were assessed as fully able to work, and 129 (13.6%)
were assessed as able to work part time (Figure 1). In contrast,
of the 4382 individuals who were 100% able to work at baseline,
only 217 (5.0%) had developed a disability that interfered with
their ability to work at 1 year of cART. When the analysis was
restricted to 580 of 947 (61.2%) patients who were unable to
work at baseline and did not change their ART regime during
the ﬁrst year of treatment, similar results were observed at 1 year
(50.9% were unable to work, 34.8% were fully able to work, and
14.3% were able to work part time).
In multivariate analysis (Table 2), predictors of recovering
full ability to work at 1 year were non-white ethnicity (odds
ratio [OR], 2.04; 95% conﬁdence interval [CI], 1.20–3.44), a
higher level of education (OR, 4.03; 95% CI, 2.47–7.48), CD4
cell counts at 1 year of at least 500 cells/µL (OR, 2.53; 95%
CI, 1.27–5.04 for CD4 cell count >500 compared with <200
cells/µL), HIV-ribonucleic acid (RNA) of <50 copies/mL at 1
year (OR, 2.06; 95% CI, 1.20–3.54), and having started cART
later in the study period (OR, 2.11; 95% CI, 1.30–3.44, for the
period 2006–2012 compared with 1998–2000). In contrast,
older age (OR, 0.55; 95% CI, .42–.72, per 10 years older), a psy-
chiatric disorder (OR, 0.24; 95% CI, .13–.47), and participating
in an opiate substitution program (OR, 0.41; 95% CI, .23–.73)
were associated with lower odds of ability to work at 1 year. Risk
factors for developing a new disability to work were older age
(OR, 1.37; 95% CI, 1.20–1.58, per 10 years older), female gender
(OR, 1.74; 95% CI, 1.32–2.29), coinfection with hepatitis C (OR,
Table 1. Characteristics of HIV-Infected Study Population With Respect to Patients’ Ability to Work at the Start of cART (n = 5800)
Characteristic at Baseline
100% Able to Work
(N = 4382)
10%–90% Able to
Work (N = 471)
0% Able to Work
(N = 947)
P Valuen % n % n %
Median age, IQR 37 31–43 38 33–45 39 34–45 <.001
Male gender 3201 73.1 293 62.2 618 65.3 <.001
Transmission
MSM 2129 48.6 111 23.6 181 19.1 <.001a
Heterosexual 1812 41.4 201 42.7 372 39.3
PWID 267 6.1 138 29.3 346 36.5
Other 174 4.0 21 4.5 48 5.1
White ethnicity 3210 73.3 379 80.5 773 81.6 <.001
Low educational attainment 994 22.9 163 35.9 325 36.1 <.001
Hepatitis C coinfection 786 17.9 191 40.6 452 47.3 <.001
Hepatitis B coinfection (antigen HBs positive) 224 5.1 20 4.3 62 6.6 .117
Prior AIDS-defining condition 532 12.1 120 25.5 354 37.8 <.001
Active injecting drug use 78 1.8 60 12.7 154 16.3 <.001
Opiate substitution program 280 6.4 83 17.6 249 26.3 <.001
Psychiatric disorder 229 5.2 66 14.0 186 19.6 <.001
Median HIV-RNA, IQR 4.7 4.1–5.2 4.8 3.9–5.3 4.9 4.2–5.5 <.001
Median CD4 cell count, IQR 263 160–372 196 65–325 157 54–291 <.001
CD4 cell count
<50 386 8.9 101 21.4 233 24.6 <.001a
50–99 276 6.3 42 8.9 108 11.4
100–199 828 18.8 94 20.0 213 22.5
200–349 1621 37.0 135 28.7 225 23.7
>350 1271 29.0 99 21.0 168 17.8
cART
PI 2354 53.7 273 58.0 598 63.1 <.001a
NNRTI 1735 39.6 155 32.9 284 30.0
Other 293 6.7 43 9.1 65 6.9
Time period
1998–2000 855 19.5 144 30.6 330 34.9 <.001a
2001–2005 1133 25.9 164 34.8 292 30.8
2006–2012 2394 54.6 163 34.6 325 34.3
Abbreviations: AIDS, acquired immune deficiency syndrome; cART, combination antiretroviral therapy; HB, hepatitis B; HIV, human immunodeficiency virus; IQR, interquartile range;MSM,men
who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitors; PI, boosted protease inhibitors; PWID, people who inject drugs; RNA, ribonucleic acid.
a χ2 test.
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1.76; 95% CI, 1.36–2.29), a prior AIDS-deﬁning disease (OR,
1.58; 95% CI, 1.16–2.46), active intravenous drug use at baseline
(OR, 4.15; 95% CI, 2.02–8.53), and psychiatric disorder (OR,
2.70; 95% CI, 1.78–4.11) (Table 3). Individuals of non-white
ethnicity (OR, 0.66; 95% CI, .51–.93), with a higher level of ed-
ucation (OR, 0.46; 95% CI, .32–.66), higher CD4 cell count (OR,
0.54; 95% CI, .33–.86 for CD4 cell count >350 compared with
<200 cells/µL), viral suppression (OR, 0.63; 95% CI, .47–.83), or
starting cART later in the study period (OR, 0.41; 95% CI,
.31–.55, for 2006–2012 compared with 1998–2000) were less
likely to be unable to work after 1 year of treatment.
At the start of cART, the primary source of incomewas a job for
3397 individuals (58.6%), insurance payments for 1198 (20.7%),
unemployment beneﬁts for 101 (1.7%), relatives for 432 (7.5%),
and savings for 46 (0.8%), whereas 626 individuals (10.8%) report-
ed 2 equivalent sources of income, such as job and assistance from
relatives. After 1 year of treatment, 3287 individuals (56.7%) re-
ported living on their job income, 1374 (23.7%) from insurance
payments, 110 (1.9%) from unemployment beneﬁts, 441 (7.6%)
on income from relatives, and 45 (0.8%) from savings, whereas
543 individuals (9.4%) reported 2 equivalent sources of income.
In the group of 947 individuals who were unable to work at base-
line, of the 310 (51.9%) who had recovered a full ability to work,
161 reported that they were living on their job income after 1 year
of treatment, and of the 508 (84.8%) with a persistent disability,
431 were living on income from insurance payments.
Time Trends in Ability to Work and the Main Source of Income
At starting cART, the overall proportion of individuals fully able
to work increased from 64.4% in the years 1998–2001 to 85.9% in
the years 2009–2012 (test for trend P < .001) (Figure 2A). A job as
the patient’s main source of income increased from 50% in the
years 1998–2001 to 62.4% in the years 2009–2012 (test for
trend P < .001), whereas insurance payments as the primary
source of income decreased from 27.4% in the years 1998–2001
to 13.5% in the years 2009–2012 (test for trend P < .001). Of the
947 people unable to work at baseline, recovering a full ability to
work at 1 year increased from 24.0% in the years 1998–2001 to
41.2% in the years 2009–2012 (test for trend P = .001) (Figure 2B).
In contrast, the proportion of people earning their living exclu-
sively from their jobs remained stable (17.0% in the years 1998–
2001 vs 18.9% in the years 2009–2012 [P = .094]), despite the fact
that insurance payments decreased from 64.4% in the years
1998–2001 to 59.2% in the years 2009–2012 (P = .052).
In a more detailed analysis, taking into account the patient’s
previous occupation type, we observed that patients reporting to
have previously been self-employed or having worked in a rel-
atives business were more likely to be unemployed when re-
gained their full ability to work compared with those who
had worked as manager, middle or lower staff, or had been an
employee (P < .001).
Changes in Ability to Work and the Main Source of Income Over a 5-
Year Period
Data on ability to work at 5 years after starting cART were avail-
able for 3029 (52.2%) of the 5800 patients included in the study.
Of this group, 2187 (72.2%) were assessed to be fully able towork,
392 (12.9%) were able to work part time, and 450 (14.9%) were
unable to work at 5 years. Of the 2264 individuals who were able
to work at 1 year, 1980 (87.5%) were still able to work at 5 years,
and only 131 (5.8%) had developed a new disability that impaired
their ability to work. Only 71% of the individuals fully able to
work at 5 years reported living on income from their jobs.
Among those unable to work at 5 years, 89.1% reported living
from insurance payments. The main reasons of the missing
data on the ability to work at 5 years in 2771 patients were the
short potential follow-up in 1892 (68.3%) patients who started
cART in the last study period (between 2006 and 2012), lost to
follow-up in 574 (20.7%), and death in 17 (6.1%) patients.
DISCUSSION
This study illustrates that the ability of treated patients to engage
in full- or part-time employment has improved signiﬁcantly
over time. Up to 50% of those unable to work at the start of
cART were able to work either full time or part time 1 year
later, and the ability to work that was regained was sustained
after 5 years of treatment. However, even in a country with
very low unemployment rates such as Switzerland, the percent-
age of fully capable HIV-infected patients for whom a job is the
primary source of income has not increased over time, which
suggests that barriers for work reintegration of persons with
HIV/AIDS still exist.
Figure 1. Medical assessment of patients’ ability to work at the start of antire-
troviral therapy and after 1 year of treatment (n = 5800). btw., between; cART, com-
bination antiretroviral therapy.
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Our results considerably extend those of earlier studies that
have reported increasing employment rates of treated HIV-in-
fected adults over time in both high- and low-income countries
[3, 7, 8, 14, 15, 17, 18], mainly as a result of the improved access
to cART, potency, tolerability, and safety of newer antiretroviral
drugs. Indeed, our study shows substantial improvement in the
ability to work in HIV-infected individuals starting cART and
also a parallel increase in the proportion of individuals report-
ing their jobs as their primary source of income, and an overall
decrease in disability payments.
In the group of individuals who were unable to work at baseline,
their regaining the ability to work also has increased considerably
over time. However, the improvement in the patients’ ability to
work has not been accompanied by an increase in their employ-
ment rates; the proportion of individuals living on their job income
and the proportion living on income from disability payments
both remained stable over time. These results are consistent with re-
cent studies that indicates lower employment rates of HIV-infected
individuals compared with the background population [14,19–23].
The discrepancy between patients’ ability to work full time and
their current employment rates, even in a country with low unem-
ployment rates, may indicate barriers to work reintegration for
HIV-infected persons that can include concerns over uncertain fu-
ture health, possible loss of beneﬁts, outdated job skills, side effects
of cART, and discrimination [7–11]. Moreover, non-HIV comor-
bidities such as cardiovascular disease, cancer, liver disease, and
neurocognitive impairment might have negatively affected re-em-
ployment rates in an aging HIV population [14, 15, 24].
In our study, recovering a full ability to work was affected pri-
marily by whether viral suppression was achieved, as well as by
Table 2. Predictors of Full Ability to Work After 1 Year of Treatment in Patients Who Were 0% Able to Work at the Start of cART (n = 947)a
Characteristic at Baseline
Univariate Analysis Multivariate Analysis
OR 95% CI P Value ORb 95% CI P Value
Age, per 10 y older 0.73 .62–.87 <.001 0.55 .42–.72 <.001
Female gender 0.85 0.64–1.13 .263 0.74 .45–1.22 .238
Non-white ethnicity 3.12 2.23–4.37 <.001 2.04 1.20–3.44 .008
Education
Low Ref. – – Ref. – –
Medium 1.02 .75–1.40 .881 2.01 1.22–3.33 .007
High 2.56 1.70–3.83 <.001 4.03 2.47–7.48 <.001
Hepatitis C coinfection 0.28 .21–.37 <.001 0.65 .41–1.05 .077
Prior AIDS-defining condition 1.53 1.16–2.02 .003 1.59 .83–1.78 .213
CD4 cells at baseline
<100 Ref. – – Ref. – –
100–199 1.67 1.39–2.02 <.001 0.69 .40–1.19 .186
200–349 2.04 2.02–2.85 <.001 0.55 .30–1.02 .058
>350 2.43 2.02–2.92 <.001 0.52 .25–1.04 .064
CD4 cells at 1 y
<200 Ref. – – Ref. – –
200–349 1.97 1.62–2.40 <.001 1.41 .86–2.32 .176
350–499 3.33 2.70–4.11 <.001 1.11 .60–2.08 .741
>500 3.84 3.16–4.67 <.001 2.53 1.27–5.04 .008
HIV-RNA >100 000 copies/mL at baseline 1.53 1.15–2.02 .003 1.31 .89–1.92 .170
HIV-RNA <50 copies/mL at 1 y 2.17 1.54–3.07 <.001 2.06 1.20–3.54 .002
Active injecting drug use 0.21 .13–.36 <.001 0.63 .29–1.36 .239
Opiate substitution program 0.18 .12–.27 <.001 0.41 .23–.73 .003
Psychiatric disorder 0.44 .30–.66 <.001 0.24 .13–.47 <.001
cART class
PI Ref. – – Ref. – –
NNRTI 1.10 .81–1.48 .540 0.78 .54–1.15 .217
Other 0.62 .34–1.12 .114 0.63 .30–1.35 .237
Time period
1998–2000 Ref. – – Ref. – –
2001–2005 1.53 1.08–2.16 .017 1.57 .98–2.51 .059
2006–2012 2.02 1.44–2.82 <.001 2.11 1.30–3.44 .003
Abbreviations: AIDS, acquired immune deficiency syndrome; cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; NNRTI, nonnucleoside
reverse-transcriptase inhibitors; OR, odds ratio; PI, boosted protease inhibitors; Ref., reference; RNA, ribonucleic acid.
a Uni- and multivariate ORs using logistic regression.
b Odds ratios adjusted for all variables listed.
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psychiatric comorbidity, current intravenous drug use, and by
psychosocial factors. Mental health is a known key mediator
for employment-related outcomes, inﬂuencing also neurocog-
nitive performance and adherence to cART [5, 23, 25, 26].
Among psychosocial factors, a higher level of formal education
was strongly associated with greater odds of being able to work
after disability. It is of interest to note that the probability of
workforce re-entry in more highly educated individuals in-
creased over time, which was also observed in other studies
[5, 14, 27–30], possibly because of increased job opportunities
and higher occupational positions. In this view, persons who
had previously worked as a manager or middle/lower staff
had a higher probability of returning to work after regaining
full ability to work.
In our study, non-white ethnicity was associated with recov-
ering from disability after starting cART. Because most non-
white people in Switzerland are immigrants from sub-Saharan
Africa, recovery of their ability to work may reﬂect improve-
ments in health after treatment of opportunistic infections
such as tuberculosis, which is not necessarily associated with se-
quelae causing long-term disability; however, it also may reﬂect
a “healthy immigrant effect”, because immigrants are generally
healthy young persons without comorbidities [31]. Nonethe-
less, only few immigrants reported earning a living from a
Table 3. Predictors for Developing a 0% Ability to Work During First Year of Treatment in Patients Who Were 100% Able to Work at the Start of cART
(n = 4382)a
Characteristic at Baseline
Univariate Analysis Multivariate Analysis
OR 95% CI P Value ORb 95% CI P Value
Age, per 10 y older 1.17 1.05–1.29 .004 1.37 1.20–1.58 <.001
Female gender 1.44 1.17–1.78 <.001 1.74 1.32–2.29 <.001
Non-white ethnicity 0.73 .58–.92 .008 0.66 .48–.91 .012
Education
Low Ref. – – Ref. – –
Medium 0.75 .60–.94 .013 0.69 .51–.93 .015
High 0.40 .30–.52 <.001 0.46 .32–.66 <.001
Hepatitis C coinfection 2.83 2.29–3.49 <.001 1.76 1.36–2.29 <.001
Hepatitis B coinfection 1.59 1.09–2.32 .017 1.59 1.04–2.46 .034
Prior AIDS-defining condition 2.01 1.57–2.58 <.001 1.58 1.16–2.17 .004
CD4 cells at baseline
<100 Ref. – – Ref. – –
100–199 0.40 .65–.75 .002 0.52 .33–.80 <.001
200–349 0.37 .56–.94 .003 0.66 .42–1.04 .076
>350 0.39 .13–.54 <.001 0.69 .41–1.17 .172
CD4 cells at 1 y
<200 Ref. – – Ref. – –
200–349 0.50 .36–.68 <.001 0.81 .54–1.20 .289
350–499 0.28 .20–.40 <.001 0.54 .33–1.34 .163
>500 0.31 .23–.42 <.001 0.60 .36–1.08 .058
CD4 cell count at the start of cART, per 100 cells/µL increase 0.90 .84–.97 .004 1.00 .90–1.10 .951
CD4 cell count at 1 y, per 100 cells/µL increase 0.88 .83–.94 <.001 0.92 .85–.99 .040
HIV-RNA >100 000 copies/mL at starting cART 1.18 .96–1.44 .119 1.11 .86–1.44 .412
HIV-RNA <50 copies/mL at 1 y 0.50 .39–.63 <.001 0.63 .47–.83 .001
Active injecting drug use 8.39 .32–13.2 <.001 4.15 2.02–8.53 <.001
Opiate substitution program 2.15 1.57–2.95 <.001 1.15 .71–1.89 .564
Psychiatric disorder 2.59 1.86–3.60 <.001 2.70 1.78–4.11 <.001
cART class
PI Ref. – – Ref. – –
NNRTI 0.81 .65–1.00 .049 1.05 .82–1.36 .684
Other 1.37 .96–1.94 .083 1.28 .83–1.96 .263
Time period
1998–2000 Ref. – – Ref. – –
2001–2005 0.55 .43–.71 <.001 0.48 .35–.66 <.001
2006–2012 0.31 .25–.40 <.001 0.41 .31–.55 <.001
Abbreviations: AIDS, acquired immune deficiency syndrome; cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; NNRTI, nonnucleoside
reverse-transcriptase inhibitors; OR, odds ratio; PI, boosted protease inhibitors; Ref., reference; RNA, ribonucleic acid.
a Uni- and multivariate ORs using logistic regression.
b Odds ratios adjusted for all variable listed.
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job, most likely because working in Switzerland is allowed only
after residence authorization has been obtained.
In patients fully able to work at baseline, cART increases the
probability of remaining employed [5, 14, 15, 29]. Factors associat-
ed with a new disability were either related to HIV disease, namely
having had a prior AIDS-deﬁning condition and not achieving
viral suppression, or to speciﬁc comorbidities such as psychiatric
disorders, current intravenous drug use, and coinfection with hep-
atitis B and hepatitis C. Prior studies have shown that non-HIV
comorbidities in HIV-infected individuals are associated with a
higher risk of hospitalization and death as well as with a loss of
employment [5, 14, 15, 32]. Hepatitis C coinfection was associated
with unemployment in many studies, mainly due to its symptoms
such as fatigue, probably contributing to lower productivity and
higher risk of job loss in these patients [33].
We acknowledge some limitations. First, information bias is
possible because assessment of a person’s ability to work relies
on the physician’s perception, and this perception depends on
the physician’s experience as well as on other comorbidities and
the nature of the patient’s profession. However, a very good cor-
relation was found between the validated instrument “work ability
index” and the simple item question “current ability to work com-
pared with the lifetime best” that is close to the physician’s assess-
ment in the SHCS [34]. Moreover, medical judgment of the ability
to work correlated very well with the main source of income. Sec-
ond, selection bias may have occurred because healthy individuals
who are less prone to being lost to follow-up may be overrepre-
sented, leading to an overestimation of the full capability of people
with an HIV infection. We mentioned in particular a healthy im-
migrant effect in people of non-white ethnicity who are generally
younger and without comorbidities.
Our study has several strengths. To our knowledge, this is the
largest comprehensive study investigating the effect of cART on
HIV-infected individuals’ ability to work over a long follow-up
period, comparing time trends and the primary sources of in-
come. More importantly, the study population included a
high proportion of women, patients who use intravenous
drugs, patients at an advanced HIV clinical stage, and patients
with comorbidities, all of which reﬂects the real-life scenarios
for HIV-infected individuals in many countries. The available
literature to date is based on the employment rates of HIV-in-
fected adults, not on medical judgments of patients’ ability to
work. Data on employment do not mirror the ability to work
because of several factors: some patients continue to work de-
spite a disability due to a fear of losing their jobs, cannot ﬁnd
a job, do not have permission to work, or decide not to work
due to family duties. The situation in Switzerland may be par-
ticularly meaningful for assessing the ability to work, because
the labor market was not as deeply affected by the international
ﬁnancial crisis and the unemployment rates remained very low
(between 3.5% and 4.2% in the years investigated) [35]. Hence,
unemployment rates were unlikely to affect the employment
status of HIV-infected individuals.
CONCLUSIONS
In conclusion, the ability to work of treated HIV-infected indi-
viduals has increased over time. Ability to work in this popula-
tion is mainly dependent on achieving viral suppression and
beneﬁcial psychosocial factors as well as on the absence of spe-
ciﬁc comorbidities. The overall proportion of individuals re-
porting a job as the main source of their income has also
increased. Our study reﬂects a better prognosis for individuals
Figure 2. Full ability to work and primary sources of income over time (A) at base-
line in the study population (n = 5800) and (B) at 1 year of combination antiretroviral
therapy in patients who were unable to work at baseline (n = 947).
HIV/AIDS and Ability to Work • OFID • 7
with HIV infection who are treated with cART. Further studies
will have to address whether speciﬁc measures, such as offer of
modiﬁed work (work accommodation) to sick workers, training
of supervisors, and communication between employer and
healthcare providers, might support reintegration and increase
employment rates of treated HIV-infected persons.
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